Allogene Therapeutics Inc (NASDAQ: ALLO) is -13.62% lower on its value in year-to-date trading and has touched a low of $1.78 and a high of $5.78 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ALLO stock was last observed hovering at around $1.82 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $1.84, the stock is -9.93% and -17.96% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.2 million and changing 1.10% at the moment leaves the stock -30.07% off its SMA200. ALLO registered -42.50% loss for a year compared to 6-month loss of -34.98%. The firm has a 50-day simple moving average (SMA 50) of $2.2662 and a 200-day simple moving average (SMA200) of $2.64265.
The stock witnessed a -11.11% gain in the last 1 month and extending the period to 3 months gives it a -31.60%, and is -5.64% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.17% over the week and 8.65% over the month.
Allogene Therapeutics Inc (ALLO) has around 233 employees, a market worth around $385.79M and $0.04M in sales. Profit margin for the company is -659137.21%. Distance from 52-week low is 3.37% and -68.14% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.64%).
with sales reaching $9.88k over the same period.The EPS is expected to grow by 36.25% this year, but quarterly earnings will post -69.36% year-over-year. Quarterly sales are estimated to shrink -52.95% in year-over-year returns.
Allogene Therapeutics Inc (ALLO) Top Institutional Holders
227.0 institutions hold shares in Allogene Therapeutics Inc (ALLO), with institutional investors hold 97.14% of the company’s shares. The shares outstanding are 209.50M, and float is at 142.63M with Short Float at 21.67%. Institutions hold 80.21% of the Float.
The top institutional shareholder in the company is FMR LLC with over 31.26 million shares valued at $72.83 million. The investor’s holdings represent 18.4816% of the ALLO Shares outstanding. As of 2024-06-30, the second largest holder is TPG GP A, LLC with 18.72 million shares valued at $43.61 million to account for 11.0663 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 16.45 million shares representing 9.7238% and valued at over $38.32 million, while VANGUARD GROUP INC holds 4.8458 of the shares totaling 8.2 million with a market value of $19.1 million.
Allogene Therapeutics Inc (ALLO) Insider Activity
#####
Allogene Therapeutics Inc disclosed in a document filed with the SEC on Dec 09 ’24 that MESSEMER DEBORAH M. (Director) sold a total of 9,136 shares of the company’s common stock. The trade occurred on Dec 09 ’24 and was made at $2.18 per share for $19916.0. Following the transaction, the insider now directly holds 0.16 million shares of the ALLO stock.
Still, SEC filings show that on Dec 05 ’24, Humer Franz B (Director) disposed off 9,221 shares at an average price of $2.16 for $19917.0. The insider now directly holds 307,507 shares of Allogene Therapeutics Inc (ALLO).
